Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia

Daichi Miyagi; Wei-Yu Chen; Bo-Jung Chen; Ying-Zhen Su; Chun-Chi Kuo; Kennosuke Karube; Shih-Sung Chuang

doi:10.1111/cyt.12890

Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia

Cytopathology. 2020 Nov;31(6):602-606. doi: 10.1111/cyt.12890. Epub 2020 Aug 9.

Authors

Daichi Miyagi¹, Wei-Yu Chen², Bo-Jung Chen³, Ying-Zhen Su⁴, Chun-Chi Kuo⁴, Kennosuke Karube⁵, Shih-Sung Chuang^{4

6}

Affiliations

¹ Faculty of Medicine, School of Medicine, University of the Ryukyus, Nishihara, Japan.
² Division of Hemato-Oncology, Department of Medicine, Chi-Mei Medical Centre, Tainan, Taiwan.
³ Department of Pathology, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
⁴ Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan.
⁵ Department of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
⁶ Department of Pathology, School of Medicine, National Taiwan University, Taipei, Taiwan.

PMID: 32681657
DOI: 10.1111/cyt.12890

No abstract available

Keywords: chronic myeloid leukaemia; clonal lymphoproliferation; dasatinib; effusion lymphoma; primary effusion lymphoma; tyrosine kinase inhibitor.

Publication types

Case Reports

MeSH terms

Body Fluids / diagnostic imaging
Cytodiagnosis*
Dasatinib / administration & dosage
Dasatinib / adverse effects
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Lymphoma, Primary Effusion / chemically induced
Lymphoma, Primary Effusion / diagnosis*
Lymphoma, Primary Effusion / pathology
Lymphoproliferative Disorders / chemically induced
Lymphoproliferative Disorders / diagnosis*
Lymphoproliferative Disorders / pathology
Middle Aged
Taiwan / epidemiology

Substances

Dasatinib